Treatment of hyperbilirubinemia
US10471132B2 · kind B2 · utility
2Cited by
0References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 27, 2015 |
| Grant date | Nov 12, 2019 |
| Priority date | — |
| Expiry date | Apr 27, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a nucleic acid sequence useful in the treatment of hyperbilirubinemia, in particular in the treatment of Crigler-Najjar syndrome. More particularly, the nucleic acid sequence of the present invention is a codon-optimized UGT1A1 coding sequence.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.